As Vice President, Antibody Technologies & CMC for Marengo Therapeutics, Madan Katragadda leads the group responsible for discovering, designing, and delivering biotherapeutic candidates with optimal biophysical and manufacturable properties. He has more than 15 years of experience discovering and developing a wide range of biotherapeutic modalities spanning peptides, fusion proteins, antibody-drug-conjugates, and multi-specific antibodies. His first foray into biotherapeutics started with the discovery of peptide-based complement inhibitors during his postdoc tenure at the University of Pennsylvania. His work led to out-licensing of an anti-C3 peptide to Apellis pharmaceuticals, who are currently testing it in several inflammatory diseases. At Pfizer, Madan led an Antibody Engineering group, built cross-functional teams to deliver on innovative ideas and new technology platforms and managed several biotherapeutic projects through internal and external collaborations. He delivered several biotherapeutic candidates to treat Inflammatory and oncology indications for preclinical/clinical development. His work at the University of Pennsylvania and Pfizer resulted in several patents and publications.

Madan holds a Ph.D. in biochemistry from the University of Connecticut and completed his postdoctoral training at the University of Pennsylvania.